New insider activity at Plus Therapeutics ( (PSTV) ) has taken place on August 25, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Robert Lenk has made a significant investment in Plus Therapeutics by purchasing 110,000 shares of the company’s stock. This transaction is valued at $52,800, indicating a strong vote of confidence in the company’s future prospects.
Recent Updates on PSTV stock
In the last 24 hours, Plus Therapeutics has experienced significant developments. The firm Maxim lowered its price target for Plus Therapeutics due to equity dilution concerns, but noted the company’s restructuring efforts as a positive move, transforming a highly dilutive equity financing into a less dilutive one. Additionally, Plus Therapeutics presented promising data from its ReSPECT-LM Phase 1 trial, showing feasible treatment options for leptomeningeal metastases with a manageable safety profile and promising efficacy. The company also reported stockholders’ equity of $3 million, satisfying Nasdaq’s listing requirements, and highlighted strong Q2 2025 financial results with a net income of $5.2 million, driven by changes in derivative instrument values. These developments have influenced analyst ratings and market perceptions, with strategic financial positioning and clinical advancements being key factors in maintaining a Buy rating despite the lowered price target.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The overall score reflects significant financial challenges and valuation concerns, partially offset by strategic corporate actions to improve compliance and financial flexibility. Technical indicators are mixed, suggesting cautious optimism.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
YTD Price Performance: -58.90%
Average Trading Volume: 31,973,202
Technical Sentiment Signal: Sell
Current Market Cap: $48.21M